Source comparison
TB-500 Research Intermediate Strategies: Protocol Comparison
Basic Maintenance 2.5mg twice weekly, flat dose None. TB-500 monotherapy Continuous for 8–12 weeks Initial tissue repair induction, baseline establishment Intermediate Escalation 2.5mg → 5mg → 2.5mg phased over 10 weeks TB-500 + BPC-157 (250–500mcg daily) 6 we
This comparison does not assign a generated winner or score.
- Basic Maintenance
- 2.5mg twice weekly, flat dose
- None. TB-500 monotherapy
- Continuous for 8–12 weeks
- Initial tissue repair induction, baseline establishment
- Intermediate Escalation
- 2.5mg → 5mg → 2.5mg phased over 10 weeks
- TB-500 + BPC-157 (250–500mcg daily)
- 6 weeks on, 3 weeks off, repeat
- Tendon, ligament, and connective tissue repair with structural remodelling
- Advanced Multi-Pathway
- 5–7.5mg twice weekly during weeks 3–6
- TB-500 + BPC-157 + GHK-Cu (1–2mg 3× weekly)
- 4 weeks on, 2 weeks off, staggered start for each peptide
- Complex injury models requiring angiogenesis, collagen synthesis, and inflammatory modulation
- Receptor Sensitivity Reset
- 2.5mg once weekly, maintenance only
- None. Monotherapy taper
- 2 weeks on, 1 week off, repeated indefinitely
- Long-term tissue health models, post-acute repair maintenance